VanEck Associates’s Avidity Biosciences RNAM Stock Holding History

VanEck Associates’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,044	Closed	-$220K	–	1452
2025 Q4	$220K	Buy	3,044 +2,120	+229%	+$137K	﹤0.01%	1273
2025 Q3	$40K	Buy	924 +110	+14%	+$4.45K	﹤0.01%	1351
2025 Q2	$23K	Sell	814 -149	-15%	-$4.44K	﹤0.01%	1354
2025 Q1	$28K	Sell	963 -352	-27%	-$11K	﹤0.01%	1326
2024 Q4	$38K	Buy	+1,315	New	+$55K	﹤0.01%	1311

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

VanEck Associates's RNAM Position: Q1 2026 in Review

VanEck Associates sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 3,044 shares — an estimated $220K sold.

VanEck Associates first reported a position in RNAM in Q4 2024 and held it in 5 quarters. The position peaked at $220K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

VanEck Associates reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
VanEck Associates sold 3,044 Avidity Biosciences shares in Q1 2026, an estimated $220K.
VanEck Associates first reported a position in Avidity Biosciences in Q4 2024 and held it in 5 quarters.
VanEck Associates's Avidity Biosciences position peaked at $220K in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.